InvestSMART

Anteris Technologies Ltd (ASX: AVR) - Announcements

Current share price for AVR : $11.590 0.41 (3.42%)+

ASX company news and announcements for Anteris Technologies Ltd (AVR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Anteris Technologies Ltd (AVR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Anteris Technologies Ltd (AVR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Anteris Technologies Ltd (AVR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$1,140 Notification regarding unquoted securities - AVR 6 Feb 2023 11:35AM $26.200 $11.690 fallen by 55.38%
$1,140 Proposed $50 Million Capital Facility 6 Feb 2023 11:14AM $26.200 $11.690 fallen by 55.38%
$1,140 Trading Halt 2 Feb 2023 10:13AM $26.200 $11.690 fallen by 55.38%
$1,140 Pause in Trading 2 Feb 2023 10:02AM $26.200 $11.690 fallen by 55.38%
$1,140 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2023 4:57PM $25.500 $11.690 fallen by 54.16%
$1,140 DurAVR First in Human Study 12 Month Results 16 Jan 2023 2:52PM $25.180 $11.690 fallen by 53.57%
$1,140 Notification of cessation of securities - AVR 20 Dec 2022 12:26PM $23.820 $11.690 fallen by 50.92%
$1,140 Cleansing Notice 2 Dec 2022 5:39PM $24.420 $11.690 fallen by 52.13%
$1,140 Application for quotation of securities - AVR 2 Dec 2022 5:33PM $24.420 $11.690 fallen by 52.13%
$1,140 Notification of cessation of securities - AVR 2 Dec 2022 5:30PM $24.420 $11.690 fallen by 52.13%
$1,140 FDA Approves Early Feasibility Study for DurAVR THV System 28 Nov 2022 9:25AM $23.000 $11.690 fallen by 49.17%
$1,140 Anteris DurAVR Comparative Study - PCR London Valves 28 Nov 2022 8:57AM $23.000 $11.690 fallen by 49.17%
$1,140 Anteris DurAVR presented at PCR London Valves 28 Nov 2022 8:54AM $23.000 $11.690 fallen by 49.17%
$1,140 Notification regarding unquoted securities - AVR 1 Nov 2022 9:59AM $22.400 $11.690 fallen by 47.81%
$1,140 Quarterly Activities/Appendix 4C Cash Flow Report 26 Oct 2022 1:22PM $21.510 $11.690 fallen by 45.65%
$1,140 R&D Refund 10 Oct 2022 1:40PM $24.480 $11.690 fallen by 52.25%
$1,140 Notification of cessation of securities - AVR 27 Sep 2022 5:05PM $24.070 $11.690 fallen by 51.43%
$1,140 Notification regarding unquoted securities - AVR 23 Sep 2022 4:34PM $24.000 $11.690 fallen by 51.29%
$1,140 Notification of cessation of securities - AVR 23 Sep 2022 3:42PM $23.810 $11.690 fallen by 50.90%
$1,140 Anteris Investor Webinar 20 Sep 2022 11:08AM $25.130 $11.690 fallen by 53.48%
$1,140 DurAVR FIH 30-Day Study Results Presented at TCT Boston 19 Sep 2022 9:58AM $25.500 $11.690 fallen by 54.16%
$1,140 Results Demonstrating Restoration of Normal Pre-Disease Flow 19 Sep 2022 8:54AM $25.500 $11.690 fallen by 54.16%
$1,140 Transcatheter Cardiovascular Therapeutics Conference 13 Sep 2022 9:09AM $23.500 $11.690 fallen by 50.26%
$1,140 Anteris Hosts Australian Interventional Cardiology Experts 5 Sep 2022 9:05AM $20.810 $11.690 fallen by 43.83%
$1,140 Cleansing Notice 30 Aug 2022 3:53PM $22.450 $11.690 fallen by 47.93%

426 - 450 of 712 results

Page 18 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.